Literature DB >> 2412271

Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

C E Frasch, W D Zollinger, J T Poolman.   

Abstract

Neisseria meningitidis serogroups B and C were originally subdivided into serotypes by the use of two different classification systems based upon type-specific bactericidal antibodies and immunoprecipitation in agar gels, respectively. The serotype specificities were later found to be associated with different major outer membrane proteins and with the lipopolysaccharide. Physiochemical characterization of the four to five major outer membrane proteins has resulted in designation of classes 1-5 on the basis of peptide mapping. The class 2 (41,000-dalton) or class 3 (38,000-dalton) protein is present in all meningococcal strains. They both are predominant proteins, show a useful degree of antigenic variation, and are epidemiologically relevant. A new serotyping nomenclature and scheme based on these two proteins and the lipopolysaccharide is therefore proposed. With use of this scheme, a meningococcal strain could be identified by serogroup to protein-serotype to lipopolysaccharide serotype, as in B:2a:L3. The class 1 (46,000-dalton) protein can be used to further define a meningococcal strain, as in B:2a:P1.2:L3.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412271     DOI: 10.1093/clinids/7.4.504

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  167 in total

1.  Multilocus sequence typing and antigen gene sequencing in the investigation of a meningococcal disease outbreak.

Authors:  I M Feavers; S J Gray; R Urwin; J E Russell; J A Bygraves; E B Kaczmarski; M C Maiden
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread.

Authors:  J Jelfs; R Munro; E Wedege; D A Caugant
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  The 1998 Senegal epidemic of meningitis was due to the clonal expansion of A:4:P1.9, clone III-1, sequence type 5 Neisseria meningitidis strains.

Authors:  P Nicolas; G Raphenon; M Guibourdenche; L Decousset; R Stor; A B Gaye
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.

Authors:  E Rosenqvist; A Musacchio; A Aase; E A Høiby; E Namork; J Kolberg; E Wedege; A Delvig; R Dalseg; T E Michaelsen; J Tommassen
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

5.  Multiple mechanisms of phase variation of PorA in Neisseria meningitidis.

Authors:  A van der Ende; C T Hopman; J Dankert
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

6.  Laboratory confirmation of meningococcal disease in Scotland, 1993-9.

Authors:  S C Clarke; J Reid; L Thom; B C Denham; G F S Edwards
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

7.  Comparison of serogroup W-135 meningococci isolated in Sweden during a 23-year period and those associated with a recent hajj pilgrimage.

Authors:  P Mölling; A Bäckman; P Olcén; H Fredlund
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

8.  Direct and rapid identification and genogrouping of meningococci and porA amplification by LightCycler PCR.

Authors:  Paula Mölling; Susanne Jacobsson; Anders Bäckman; Per Olcén
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

9.  Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination.

Authors:  D A Ala'Aldeen; K R Neal; K Ait-Tahar; J S Nguyen-Van-Tam; A English; T J Falla; P M Hawkey; R C Slack
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

10.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.